Clinical Trial Update: Evaluation of Safety Following Immune Tolerance Induction Treatment With Turoctocog Alfa in Patients With Haemophilia A Following Inhibitor Development in NN7170-4213 Trial [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating safety of immune tolerance induction with turoctocog alfa in Haemophilia A patients with inhibitors; study terminated with poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Haemophilia

Drugs mentioned

• Turoctocog alfa (turoctocog alfa)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Haemophilia A | Phase 3 | Status: TERMINATED | Results posted: 2020-07-07